Submitted: 02 Jun 2022
Revision: 12 Jun 2022
Accepted: 18 Jun 2022
ePublished: 30 Jun 2022
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - Firefox Plugin)

Avicenna J Pharm Res. 2022;3(1): 32-36.
doi: 10.34172/ajpr.2022.1065
  Abstract View: 110
  PDF Download: 59

Original Article

Comparison of the Total Side Effects of Injectable Disease-Modifying Drugs for the First-line Treatment of Relapsing-Remitting Multiple Sclerosis

Masoud Ghiasian 1 ORCID logo, Seyedeh Anis Rashidizad 2, Mojdeh Mohammadi 3, Younes Mohammadi 4, Sara Ataei 2* ORCID logo

1 Department of Neurology, Hamadan University of Medical Sciences, Hamadan, Iran
2 Department of Clinical Pharmacy, School of Pharmacy, Hamadan University of Medical Sciences, Hamadan, Iran
3 Department of Pharmacology & Toxicology, School of Pharmacy, Hamadan University of Medical Sciences, Hamadan, Iran
4 Social Determinants of Health Research Center, School of Public Health, Hamadan University of Medical Sciences, Hamadan, Iran
*Corresponding Author: Sara Ataei, Email: s.ataei@umsha.ac.ir


Background: Physicians generally prescribe disease-modifying drugs (DMDs) to reduce the frequency and severity of relapses in multiple sclerosis (MS). The frequency and severity of side effects are important factors that can affect drug choice. The main purpose of this analysis was to evaluate the side effects of different types of first-line injectable DMDs and determine which drug has more complications, and which drug has the most drug discontinuation rates due to severe side effects.

Methods: Four groups of injectable DMDs were compared in 386 relapsing-remitting MS (RRMS) patients in the range of 15-60 years who were controlled with these drugs for at least two years (2017-2019) and had the Expanded Disability Status Scale (EDSS) from 0 to 5 without underlying heart and liver diseases. Eventually, the frequency of side effects was determined for each group, and the collected data were compared in each treatment group.

Results: In the present study, 31% of patients had no complications. Most of the reported complications (68.25%) were mild in severity, and only 15.5% of the patients discontinued their therapy.

Conclusion: The findings recommend that the side effects of different DMDs used for RRMS should be studied more comprehensively in clinical and post-marketing trials. Additionally, physicians should take note of these side effects of DMDs in their prescriptions to increase patients’ adherence to therapy.

Please cite this article as follows: Ghiasian M, Rashidizad SA, Mohammadi M, Mohammadi Y, Ataei S. Comparison of the total side effects of injectable disease-modifying drugs for the first-line treatment of relapsing-remitting multiple sclerosis. Avicenna J Pharm Res. 2022; 3(1):32-36. doi:10.34172/ajpr.2022.1065
First Name
Last Name
Email Address
Security code

Abstract View: 111

Your browser does not support the canvas element.

PDF Download: 59

Your browser does not support the canvas element.